Indeed, there has been debate as to whether any benefit reported with cholinesterase inhibitors in vascular dementia trials is due to a true effect on vascular dementia, or an effect on concurrent Alzheimer’s pathology. The gene discussed is BCHE; the disease is vascular dementia.